Activate Now
 
ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Big step towards cure for HIV and other lifelong viral infections

SURVEY RESULTS: Attitudes About Fatigue

Superfood Trio: Ginger, Turmeric, and Carrots?

Rejuvenate Your Skin Naturally With Sea Buckthorn Oil

A Smile

Can Drinking More Water Help You Lose Weight?

Resveratrol’s Link to Slowing Alzheimer’s

Tropical Turmeric Carrot Juice & Smoothie

Most Everyone Can Use More Vitamin D

Omega-3s May Improve Healing After a Heart Attack

 
Print Page
Email Article

Half of CFS patients with high HHV-6 & EBV titers improve 30% or better on Valcyte: Montoya

  [ 10 votes ]   [ 1 Comment ]
www.ProHealth.com • October 16, 2012


Article:
Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers
- Source: Journal of Medical Virology, Oct 10, 2012

By Tessa Watt, Jose G Montoya, et al.

[Note: Dr. Montoya has studied the impact of the antiviral valganciclovir (Valcyte®) on ME/CFS patients affected by these viruses for years. This report suggests longer term treatment may be linked to better response.]

Abstract:
Valganciclovir has been reported to improve physical and cognitive symptoms in patients with chronic fatigue syndrome (CFS) with elevated human herpesvirus 6 (HHV-6) and Epstein–Barr virus (EBV) IgG antibody titers [concentrations].

This study investigated whether antibody titers against HHV-6 and EBV were associated with clinical response to valganciclovir in a subset of CFS patients.

An uncontrolled, unblinded retrospective chart review was performed on 61 CFS patients treated with 900mg valganciclovir daily (55 of whom took an induction dose of 1,800mg daily for the first 3 weeks).

Antibody titers were considered high if:

• HHV-6 IgG was 1:320 or greater,

• EBV viral capsid antigen (VCA) IgG was 1:640 or greater,

• And EBV early antigen (EA) IgG was 1:160 or greater.

Patients self-rated physical and cognitive functioning as a percentage of their functioning prior to illness.

Patients were categorized as responders if they experienced at least 30% improvement in physical and/or cognitive functioning.

Thirty-two patients (52%) were categorized as responders.

Among these:

• 19 patients (59%) responded physically

• And 26 patients (81%) responded cognitively.

Baseline antibody titers showed no significant association with response.

After treatment, the average change in physical and cognitive functioning levels for all patients was +19% and +23%, respectively (P<0.0001). Longer treatment was associated with improved response (P=0.0002).

No significant difference was found between responders and non-responders among other variables analyzed.

Valganciclovir treatment, independent of the baseline antibody titers, was associated with self-rated improvement in physical and cognitive functioning for CFS patients who had positive HHV-6 and/or EBV serologies.

Longer valganciclovir treatment correlated with an improved response.

Source: Journal of Medical Virology, Oct 10, 2012;84(12), pp 1967-1974. DOI: 10.1002/jmv.23411, by Watt T, Oberfoell S, Balise R, Lunn MR, Kar AK, Merrihew L, Bhangoo MS, Montoya JG. Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University Medical Center, Palo Alto, California; University of Michigan Medical School, Ann Arbor; David Geffen School of Medicine, UCLA, Los Angeles, California; Brigham and Women’s Hospital, Boston, Massachusetts; San Diego School of Medicine, University of California, USA. [Email: Jose G Montoya Gilberto@stanford.edu]





Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® Energy NADH™ 12.5mg Optimized Curcumin Longvida®

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments Post a Comment

Longer valganciclovir treatment correlated with an improved response.
Posted by: IanH
Oct 16, 2012
It would have been great if this improved response over longer term treatment could have been enumerated.
Reply Reply
 
Natural Pain Relief Supplements

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health

Natural Remedies

Natural Relief for Soreness, Pain and Swelling - Putting Out the Fire Natural Relief for Soreness, Pain and Swelling - Putting Out the Fire
Coenzyme Q10 - The Energy Maker Coenzyme Q10 - The Energy Maker
Restore Youthful Cognition and Well-Being Restore Youthful Cognition and Well-Being
Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial
How I Found My Long-Lost Energy How I Found My Long-Lost Energy

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE AND SAVE 15% NOW*
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map